University of Hertfordshire

Immunotherapy in Urological Tumors

Research output: Contribution to journalArticlepeer-review

View graph of relations
Original languageEnglish
Pages (from-to)15–20
Number of pages6
JournalReviews in Urology
Volume21
Issue1
Publication statusAccepted/In press - 25 Jan 2021

Abstract

The past decade has seen significant improvement in our understanding of tumor biological features, which has led to use of anti-programmed-death 1 (PD-1) and anti-PDligand-1 (PD-L1) agents and cytotoxic T lymphocytes antigen 4 (CTLA-4) inhibitors in a multitude of cancers. These immunotherapeutic agents have shown activity in melanoma, lung, head and neck, colorectal, urological, and other cancers. This article details the use of immunotherapy agents in urothelial, renal, prostate, and testicular tumors.

Notes

© 2019 MedReviews.

ID: 26051471